Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, United Kingdom.
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
J Med Chem. 2022 Jun 9;65(11):7489-7531. doi: 10.1021/acs.jmedchem.2c00227. Epub 2022 May 25.
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to the 1.8 million deaths caused by COVID-19. The World Health Organization has stated that new TB drugs must be developed to end this pandemic. After decades of neglect in this field, a renaissance era of TB drug discovery has arrived, in which many novel candidates have entered clinical trials. However, while hundreds of molecules are reported annually as promising anti-TB agents, very few successfully progress to clinical development. In this Perspective, we critically review those anti-TB compounds published in the last 6 years that demonstrate good efficacy against . Additionally, we highlight the main challenges and strategies for developing new TB drugs and the current global pipeline of drug candidates in clinical studies to foment fresh research perspectives.
在过去的 2000 年里,结核病(TB)造成的死亡人数超过了任何其他传染病。仅在 2020 年,结核病就导致全球 150 万人死亡,这与 COVID-19 造成的 180 万人死亡相当。世界卫生组织表示,必须开发新的结核病药物来结束这一大流行病。经过几十年在这一领域的忽视,结核病药物发现的复兴时代已经到来,许多新的候选药物已经进入临床试验。然而,虽然每年有数百种分子被报道为有前途的抗结核药物,但很少有药物能成功进入临床开发。在本观点中,我们批判性地回顾了过去 6 年发表的那些对 具有良好疗效的抗 TB 化合物。此外,我们还强调了开发新的结核病药物的主要挑战和策略,以及目前在临床试验中处于临床研究阶段的候选药物的全球管道,以激发新的研究视角。